What is the recommended dosing, monitoring, and contraindications for terlipressin (terliressine) in adult patients with type‑1 hepatorenal syndrome?

Terlipressin for Type-1 Hepatorenal Syndrome

Dosing Regimen

Start terlipressin at 1 mg IV bolus every 4-6 hours combined with albumin, escalating to 2 mg every 4-6 hours if serum creatinine fails to decrease by ≥25% by day 3-4, with a maximum dose of 12 mg/day for up to 14 days. 1

Initial Dosing

• Begin with 1 mg IV bolus every 4-6 hours administered as a slow push over 2 minutes through a peripheral or central line 1, 2
• No dilution is required for bolus administration 3
• Continue this dose for the first 3 days 1

Dose Escalation Protocol

• Increase to 2 mg every 4-6 hours on day 4 if serum creatinine has not decreased by at least 25-30% from baseline 1, 3
• Maximum total daily dose is 12 mg/day regardless of administration method 1, 3
• Continue treatment until serum creatinine decreases below 1.5 mg/dL (133 μmol/L), typically to 1.0-1.2 mg/dL (88-106 μmol/L) 1
• Median time to response is 14 days 1

Alternative Continuous Infusion

• Start at 2 mg/day as continuous IV infusion, which provides equal efficacy with lower total daily doses and fewer ischemic side effects compared to bolus dosing 1, 3
• Escalate every 24-48 hours up to maximum 12 mg/day if serum creatinine does not decrease by ≥25% 3

---

Mandatory Albumin Co-Administration

Terlipressin must always be combined with albumin—monotherapy achieves only 25% response rate versus 77% with combination therapy. 3, 4

Albumin Dosing Schedule

• Day 1: 1 g/kg IV (maximum 100 g) 1, 3, 2
• Subsequent days: 20-40 g/day IV until treatment completion 1, 3
• The combination improves circulatory function by increasing effective arterial volume while terlipressin reduces splanchnic vasodilation 5, 4

Critical Albumin Management

• Reassess need for continued albumin after 1-2 days based on volume status to avoid excessive volume expansion 3
• Consider point-of-care ultrasonography for volume assessment 3
• Judicious albumin use is critical as excessive volume expansion increases respiratory failure risk (11% vs 2% placebo) 3, 2

---

Monitoring Requirements

Pre-Treatment Assessment

Obtain baseline oxygen saturation (SpO₂) and do not initiate terlipressin if SpO₂ <90% on room air or supplemental oxygen—this is an absolute contraindication per FDA warning. 1, 3, 2

Additional baseline assessments include:

• Electrocardiogram to screen for ischemic heart disease 3
• ACLF grade assessment (EASL-CLIF criteria) 1, 3, 2
• Volume status evaluation 3, 2
• Baseline serum creatinine documentation 2

During Treatment Monitoring

• Continuous pulse oximetry throughout treatment 3, 2
• Discontinue terlipressin immediately if SpO₂ decreases below 90% 2
• Vital signs including pulse oximetry every 2-4 hours 3
• Daily serum creatinine monitoring looking for ≥25-30% reduction by days 3-4 3
• Monitor for ischemic complications (occur in ~12% of patients): abdominal pain, chest pain, digital ischemia, arrhythmias 1, 3
• Monitor for respiratory failure (occurs in 14% vs 5% placebo) 1, 2

Setting Requirements

• ICU monitoring is mandatory for patients with ACLF grade 3 (≥3 organ failures) due to increased respiratory failure risk 1, 3, 2
• Patients with ACLF grade <3 can be managed on regular wards with appropriate monitoring 3
• Central line placement is not required—peripheral IV access is sufficient 3, 2

---

Contraindications

Absolute Contraindications

• SpO₂ <90% on room air or supplemental oxygen 3, 2
• Active coronary, peripheral, or mesenteric ischemia 3, 2
• Hypoxia or worsening respiratory symptoms 2

Relative Contraindications and Cautions

• Exercise extreme caution in patients with ACLF-3 as defined by EASL-CLIF criteria—these patients have significantly increased risk of respiratory failure 1
• Known cardiac failure or underlying respiratory conditions, especially with baseline hypoxemia 1
• Severe cardiovascular or ischemic conditions (most studies excluded these patients) 1
• Serum creatinine >5 mg/dL (440 μmol/L) indicates patients are unlikely to benefit from treatment 1, 2

---

Predictors of Treatment Response

Favorable Prognostic Factors

• Baseline bilirubin <10 mg/dL (170 μmol/L) 1, 3
• Baseline serum creatinine <5 mg/dL (440 μmol/L) 1, 3
• Mean arterial pressure increase ≥5-10 mmHg by day 3 of treatment 1, 3
• Lower ACLF grade (ACLF-2 and -3 associated with lower probability of response) 1
• Child-Pugh score ≤13 at time of HRS diagnosis 6

Response Definitions

• Complete response: serum creatinine returning to within 0.3 mg/dL of baseline 3
• Partial response: regression of AKI stage with serum creatinine ≥0.3 mg/dL from baseline or ≥25% reduction in creatinine 3
• HRS reversal rate: 36-44% of patients achieve reversal with terlipressin plus albumin 1, 3

---

Alternative Vasoconstrictor Therapy

If terlipressin fails, is contraindicated, or unavailable, switch to norepinephrine 0.5 mg/hour (or 5 μg/min) continuous IV infusion, titrated up to 3 mg/hour (or 10 μg/min) to achieve MAP increase >10 mmHg above baseline. 1, 3

Norepinephrine Considerations

• Requires ICU admission and central line placement 1
• Similar response rates of 39-70% compared to terlipressin 3
• In ACLF context, terlipressin demonstrates superiority over norepinephrine with 28-day survival of 48.3% vs 20% (p=0.001) 1, 3
• Norepinephrine is the first drug of choice in patients with AKI and shock 1

Octreotide/Midodrine Alternative

• Octreotide 200 μg subcutaneously three times daily plus midodrine titrated to maximum 12.5 mg orally three times daily 1
• Target mean blood pressure increase of 15 mm Hg 1
• Can be administered outside ICU and even at home 1
• Less robust evidence compared to terlipressin 1

---

Common Pitfalls and How to Avoid Them

Volume Overload Management

• Do not continue aggressive albumin administration beyond initial days without reassessing volume status 3
• Manage intravascular volume overload by reducing or discontinuing albumin and/or other fluids 2
• Use judicious diuretics when appropriate 2
• Temporarily interrupt, reduce, or discontinue terlipressin until volume status improves 2

Inadequate Dose Escalation

• Do not continue same dose beyond day 3-4 if creatinine reduction is <25-30% 3
• Failure to escalate dose appropriately reduces treatment efficacy 1

Delayed Treatment Initiation

• Initiate therapy early in the course of HRS—ACLF grade is the major determinant of response, with ACLF-2 and -3 associated with lower probability of response 1
• Every 1 mg/dL drop in serum creatinine with vasoconstrictor therapy results in 27% reduction in relative risk of mortality 1

Respiratory Monitoring Failures

• Never initiate or continue terlipressin without continuous pulse oximetry 3, 2
• Respiratory failure is the most serious adverse effect, occurring in 14% of terlipressin-treated patients 1, 2
• Complex interplay of hemodynamics, subtle cirrhotic cardiomyopathy (diastolic dysfunction), and volume overload contribute to respiratory compromise 1

Ischemic Complications

• Ischemic events occur in approximately 12% of patients: angina, arrhythmia, digital ischemia, intestinal ischemia 1, 3
• Terlipressin can stimulate intestinal motility, leading to abdominal pain and diarrhea 1
• Permanent withdrawal required in only small proportion of cases with ischemic complications 7

---

Clinical Outcomes

Survival Impact

• Complete reversal of HRS-1 is associated with significantly better survival compared to nonresponders 1
• Patients with confirmed HRS reversal who received terlipressin had significantly better day 90 survival compared to those without reversal (p<0.001) 8
• Terlipressin reduces need for renal replacement therapy: 28.1% vs 35.9% placebo by day 30 (p=0.040) 9
• More patients alive and RRT-free by day 90: 36.9% vs 28.5% placebo (p=0.030) 9